431 Results

People

  1. Motzer
    Motzer
  2. Voss
    Voss
  3. Feldman
    Feldman
  4. Antonescu
    Antonescu
  5. Hakimi
    Hakimi
  6. Patil
    Patil
  7. Abou-Alfa
    Abou-Alfa
  8. DeMatteo
    DeMatteo
  9. Ginsberg
    Ginsberg
  10. Reidy
    Reidy

Groups

  1. Department of Medicine (315)
  2. Solid Tumor Oncology Division (288)
  3. Genitourinary Oncology Service (198)
  4. Surgery (60)
  5. GSK Faculty (47)
  6. Department of Pathology and Laboratory Medicine (44)
  7. Gastrointestinal Oncology Service (41)
  8. Radiology, Department of (38)
  9. Survivorship Research (34)
  10. Tow Center for Developmental Oncology (TCDO) (33)
  1. "sunitinib"
Formats
  1. Journal Article (391)
  2. Review (21)
  3. Editorial (5)
  4. Research Letter (4)
  5. Book Section (3)
  6. Correspondence (3)
  7. Guidelines (3)
  8. Miscellaneous (1)
Groups
  1. Department of Medicine (315)
  2. Solid Tumor Oncology Division (288)
  3. Genitourinary Oncology Service (198)
  4. Surgery (60)
  5. GSK Faculty (47)
  6. Department of Pathology and Laboratory Medicine (44)

More Groups

People
  1. Robert Motzer (159)
  2. Martin Voss (24)
  3. Darren Feldman (23)
  4. Robert Maki (20)
  5. Chung-Han Lee (17)
  6. Cristina Antonescu (17)

More People

Years
  1. 2025 (7)
  2. 2024 (18)
  3. 2023 (18)
  4. 2022 (18)
  5. 2021 (13)
  6. 2020 (18)

More Years

Publications
  1. Journal of Clinical Oncology (19)
  2. Clinical Cancer Research (18)
  3. European Urology (18)
  4. Journal of the National Comprehensive Cancer Network (17)
  5. Cancer (14)
  6. European Journal of Cancer (13)

More Publications

Publishers
  1. Elsevier Inc. (69)
  2. Elsevier Science, Inc. (38)
  3. Springer (31)
  4. Wiley Blackwell (30)
  5. Oxford University Press (29)
  6. Nature Publishing Group (27)

More Publishers

Results (431)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mucinous tubular and spindle-cell carcinoma of the kidney: Clinical features, genomic profiles, and treatment outcomes
    Journal Article

    Ged, Y.; Chen, Y. B.; Knezevic, A.; Donoghue, M. T. A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Hakimi, A. A.; Russo, P.; more...
    Clinical Genitourinary Cancer (2019)

    Fulltext@MSK | Save
  • Immune checkpoint blockade plus axitinib for renal-cell carcinoma - Drs. Motzer and Huang reply
    Correspondence

    Motzer, R. J.; Huang, B.
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save
  • Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity
    Journal Article

    Calizo, R. C.; Bhattacharya, S.; van Hasselt, J. G. C.; Wei, C.; Wong, J. S.; Wiener, R. J.; Ge, X.; Wong, N. J.; Lee, J. J.; Cuttitta, C. M.; more...
    Nature Communications (2019)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Journal Article

    Shah, A. Y.; Kotecha, R. R.; Lemke, E. A.; Chandramohan, A.; Chaim, J. L.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale
    Journal Article

    Grünwald, V.; Powles, T.; Choueiri, T. K.; Hutson, T. E.; Porta, C.; Eto, M.; Sternberg, C. N.; Rha, S. Y.; He, C. S.; Dutcus, C. E.; more...
    Future Oncology (2019)

    Fulltext@MSK | Save
  • Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): A randomised, phase 3 trial
    Journal Article

    Cella, D.; Grünwald, V.; Escudier, B.; Hammers, H. J.; George, S.; Nathan, P.; Grimm, M. O.; Rini, B. I.; Doan, J.; Ivanescu, C.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • Genomic differences between “primary” and “secondary” muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy
    Editorial

    Pietzak, E. J.; Zabor, E. C.; Bagrodia, A.; Armenia, J.; Hu, W.; Zehir, A.; Funt, S.; Audenet, F.; Barron, D.; Maamouri, N.; more...
    European Urology (2019)

    Fulltext@MSK | Save
  • Real-time genomic characterization of metastatic pancreatic neuroendocrine tumors has prognostic implications and identifies potential germline actionability
    Journal Article

    Raj, N.; Shah, R.; Stadler, Z.; Mukherjee, S.; Chou, J.; Untch, B.; Li, J.; Kelly, V.; Osoba, M.; Saltz, L. B.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Important group differences on the Functional Assessment of Cancer Therapy–Kidney Symptom Index Disease-Related Symptoms in patients with metastatic renal cell carcinoma
    Journal Article

    Cella, D.; Motzer, R. J.; Rini, B. I.; Cappelleri, J. C.; Ramaswamy, K.; Hariharan, S.; Arondekar, B.; Bushmakin, A. G.
    Value in Health (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study
    Journal Article

    Amin, A.; Plimack, E. R.; Ernstoff, M. S.; Lewis, L. D.; Bauer, T. M.; McDermott, D. F.; Carducci, M.; Kollmannsberger, C.; Rini, B. I.; Heng, D. Y. C.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save